Bristol-Myers Squibb's (BMY) 'Disappointing' Opdivo Data in NSCLC has No Impact on Ratings - Moody's
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $48.45 -0.12%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 4.7%
EPS Growth %: -21.5%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 4.7%
EPS Growth %: -21.5%
Join SI Premium – FREE
Moody's Investors Service commented that Bristol-Myers Squibb's (NYSE: BMY) disappointing clinical trial result for Opdivo in first-line lung cancer is a setback because this indication represented a sizeable growth opportunity. There is no impact on Bristol's A2/Prime-1 ratings or stable rating outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Upgrades Barry Callebaut AG (BARN:SW) (BYCBF) to Buy
- Oppenheimer Upgrades Avalo Therapeutics (AVTX) to Outperform following AVTX-009 acquisition
- Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals
Create E-mail Alert Related Categories
Credit RatingsRelated Entities
Moody's Investors ServiceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
